Detalhe da pesquisa
1.
Safety and efficacy of filgotinib for Japanese patients with RA and inadequate response to MTX: FINCH 1 52-week results and FINCH 4 48-week results.
Mod Rheumatol
; 33(4): 668-679, 2023 Jul 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35920102
2.
Long-term safety and efficacy of filgotinib treatment for rheumatoid arthritis in Japanese patients naïve to MTX treatment (FINCH 3).
Mod Rheumatol
; 33(4): 657-667, 2023 Jul 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35921235
3.
Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial.
Lancet
; 397(10292): 2372-2384, 2021 06 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-34090625
4.
Impact of filgotinib on sacroiliac joint magnetic resonance imaging structural lesions at 12 weeks in patients with active ankylosing spondylitis (TORTUGA trial).
Rheumatology (Oxford)
; 61(5): 2063-2071, 2022 05 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-34352069
5.
Efficacy and safety of filgotinib in Japanese patients with refractory rheumatoid arthritis: Subgroup analyses of a global phase 3 study (FINCH 2).
Mod Rheumatol
; 32(1): 59-67, 2022 01 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33274687
6.
Efficacy and safety of filgotinib in combination with methotrexate in Japanese patients with active rheumatoid arthritis who have an inadequate response to methotrexate: Subpopulation analyses of 24-week data of a global phase 3 study (FINCH 1).
Mod Rheumatol
; 32(2): 263-272, 2022 Feb 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-34910188
7.
Efficacy and safety of filgotinib alone and in combination with methotrexate in Japanese patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: Subpopulation analyses of 24-week data of a global phase 3 study (FINCH 3).
Mod Rheumatol
; 32(2): 273-283, 2022 Feb 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-34910203
8.
Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial.
Ann Rheum Dis
; 80(7): 848-858, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33504485
9.
Filgotinib in combination with methotrexate or as monotherapy versus methotrexate monotherapy in patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: the phase 3, randomised controlled FINCH 3 trial.
Ann Rheum Dis
; 80(6): 727-738, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33452004
10.
Effect of filgotinib on health-related quality of life in active psoriatic arthritis: a randomized phase 2 trial (EQUATOR).
Rheumatology (Oxford)
; 59(7): 1495-1504, 2020 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31624837
11.
Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial.
Lancet
; 392(10162): 2367-2377, 2018 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30360969
12.
Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial.
Lancet
; 392(10162): 2378-2387, 2018 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30360970
13.
Effect of Filgotinib vs Placebo on Clinical Response in Patients With Moderate to Severe Rheumatoid Arthritis Refractory to Disease-Modifying Antirheumatic Drug Therapy: The FINCH 2 Randomized Clinical Trial.
JAMA
; 322(4): 315-325, 2019 07 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-31334793
14.
Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial.
Lancet
; 389(10066): 266-275, 2017 01 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-27988142
15.
Influence of age and renal impairment on the steady state pharmacokinetics of filgotinib, a selective JAK1 inhibitor.
Br J Clin Pharmacol
; 84(12): 2779-2789, 2018 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-30088677
16.
Mucosal p-STAT1/3 correlates with histologic disease activity in Crohn's disease and is responsive to filgotinib.
Tissue Barriers
; 11(2): 2088961, 2023 04 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-35762272
17.
Efficacy and safety of filgotinib as induction and maintenance therapy for Japanese patients with moderately to severely active ulcerative colitis: a post-hoc analysis of the phase 2b/3 SELECTION trial.
Intest Res
; 21(1): 110-125, 2023 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-35263963
18.
Filgotinib: A Clinical Pharmacology Review.
Clin Pharmacokinet
; 61(6): 819-832, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35637376
19.
Effect of filgotinib, a selective JAK 1 inhibitor, with and without methotrexate in patients with rheumatoid arthritis: patient-reported outcomes.
Arthritis Res Ther
; 20(1): 57, 2018 03 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-29566740
20.
Clinical Confirmation that the Selective JAK1 Inhibitor Filgotinib (GLPG0634) has a Low Liability for Drug-drug Interactions.
Drug Metab Lett
; 10(1): 38-48, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-26693854